Amendments to the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

1-19. (cancelled)

20. (presented previously) A compound of Formula III:

Formula III

or a pharmaceutically acceptable salt thereof.

21. (currently amended) A method of treating diseases of the liver

hepatocellular carcinoma in an animal comprising administering a compound of Formula

III:

Attorney Docket No. 2358.0180002/RWE/AES

Formula III

or a pharmaceutically acceptable salt thereof.

22-23. (cancelled)

24. (currently amended) A method of preventing recurrence of hepatocellular carcinoma eancers in the liver after medical or surgical treatment for said hepatocellular carcinoma eancers in an animal comprising administering a compound of Formula III:

Formula III

or a pharmaceutically acceptable salt thereof.

- 25. (currently amended) The method of claim 24 wherein said animal is in remission from said hepatocellular carcinoma eancers and said administration of [[a]] the compound of Formula III prevents further development of said eancers hepatocellular carcinoma.
- 26. (currently amended) A method of increasing the therapeutic index of cytarabine for the treatment of a liver disease hepatocellular carcinoma comprising administering a compound of Formula III:

Formula III

or a pharmaceutically acceptable salt thereof.

27. (currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of Formula III:

Attorney Docket No. 2358.0180002/RWE/AES

Formula III

or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipients excipient.

28. (currently amended) A pharmaceutical composition comprising a pharmaceutically effective amount of Formula III:

Formula III

or a pharmaceutically acceptable salt thereof,

and a pharmaceutically effective amount of an oncolytic agent, or salts \underline{a} salt thereof, and \underline{a} pharmaceutically acceptable excipients excipient.

29. (currently amended) The pharmaceutical composition of claim 28 wherein said oncolytic agent is selected from the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, duanbrubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, mercaptopuirne, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, etoposide, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopuririe mercaptopurine, thioguanine, azatoxin, camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin, pirarubin, nrocarzinostatin neocarzinostatin, calicheamicin, esperamicin, and luroteca.

30. (currently amended) A method of treating eancers of the liver

hepatocellular carcinoma in an animal comprising administering a compound of Formula

III:

Formula III

or a pharmaceutically acceptable salt thereof,

and comprising administering a pharmaceutically effective amount of an oncolytic agent.

- 31. (presented previously) The method of claim 30 wherein said oncolytic agent and said compound of Formula III are administered separately.
- 32. (presented previously) The method of claim 30 wherein said oncolytic agent and said compound of Formula III are administered simultaneously.
- 33. (currently amended) The method of claim 30 wherein said oncolytic agent is selected from the group consisting of busulfan, carboplatin, cisplatin, miriplatin, temozolomide, thiotepa, melphalan, ifosfamide, cyclophosphamide, chlorambucil, doxorubicin, duanorubicin, epirubicin, idarubicin, plicamycin, valrubicin, dactinomycin, gemcitabine, floxuridine, fluorouracil, mercaptopurine, thioguanine, methotrexate, mitomycin, etoposide, paclitaxel, docetaxel, irinotecan, topotecan, etoposide, teniposide, nedaplatin, carmustine, doxifluridine, cladribine, fludarabine, carmustine, mercaptopurine, thioguanine, azatoxin, camptothecin, lurtotecan, camptothecin, 9-aminocamptothecin, pirarubin, nrocarzinostatin neocarzinostatin, calicheamicin, esperamicin, and luroteca.